SAN DIEGO--(BUSINESS WIRE)--Critical Diagnostics announced today that results of a post-hoc analysis of a previously described prospective, randomized, controlled study of well treated heart failure patients showed that patients, at baseline above the FDA-cleared threshold of 35 ng/mL for the company’s cardiac biomarker ST2, who were taking low doses of beta blocker were almost seven times as likely to experience a cardiovascular event, such as an unplanned hospitalization, than patients who had low ST2 levels and were on high-doses of beta blocker.
Help employers find you! Check out all the jobs and post your resume.
